The E uropean R esearch I nitiative (ERIA) was instigated to coordinate research into Anaplastic Lymphoma Kinase ( ALK )-related malignancies to facilitate the development of less-toxic and more efficacious therapies. ALK is increasingly recognized as a prevalent oncogene in a number of human malignancies and therefore poses a prominent clinical problem.
ERIA ( www.erialcl.net ) is an existing and functional network of 13 partners. ALK is increasingly recognized as a prevalent oncogene in a number of human malignancies and therefore poses a prominent clinical problem, which requires coordinated research into its oncogenic mechanisms. ERIA now conducts a collaborative multidisciplinary research program at the interface of biomedical and bio-mechanistic approaches, which will be an excellent environment to train the next generation of European scientists. The 15 recruited fellows will be incorporated into international academic study groups (all partners of the ERIA network) to perform high caliber research and also will be exposed to environments from other sectors to broaden their experience.Secondments will include technical training within individual laboratories and SMEs - TissueGnostics, Galkem, Cambridge Life Sciences, Sofigen and Varionostics - as well as large Pharma (Roche). Training through research will be complemented with a balanced program of transferable skills and access to local courses. The training of each fellow will be guided by a personal career development plan and supervised by a PhD committee panel. The primary goal of the network is to train the recruited fellows by participating in an internationally competitive research program and integrating them into an international network. Thereby providing competence in state-of-the-art research and development at the forefront of translational science.
This project has received funding from the European Union's FP7 program under grant agreement No 612471.
Marie Curie Initiative: Innovative Training Networks (ITN)